A review on absorption enhancer and bioenhancer
Keywords:
bioenhancer, absorption enhancer, bioavailabilityAbstract
Poor permeability of orally administered drugs is the major factor limiting the bioavailability of orally administered drugs. The unique barrier properties of the gastro-intestinal membrane, intestinal and presystemic metabolism, intersubject variability also contributors to poor permeability and bioavailability of the drugs. Bioenhancer can benefit the drugs with this problem, especially BCS class III and class IV drugs. Different mechanisms have been established to understand the permeation enhancement effect of different permeation enhancers; their understanding can facilitate the selection of suitable absorption promoters for drugs having specific physicochemical properties. However, certain issues associated with development of absorption promoter technology like lack of in vitro and in vivo correlation of efficacy, reproducibility, and safety. Therefore instead of chemical permeation enhancer herbal bioenhancer is more acceptable due to their better safety profile.
Downloads
References
Hayden Thomas, Shobha Bhattachar, Linda Hitchingham, Philip Zocharski, Maryanne Naath, Narayanan Surendran, Chad L Stoner & Ayman El-Kattan. The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol. (2006) 2(4):591-608.
Schmid EF and Smith DA. Is pharmaceutical R&D is just a game of chance or can strategy make a difference? Drug Discov Today 2004;9:18–26.
Swenson ES, Milisen WB, Curatolo W. 1994. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res 11:1132–1142.
Aungst, B.J., 2000. Intestinal permeation enhancers. J. Pharm. Sci. 89, 429–442.
Mishra A et al. Oral Absorption Promoters: Opportunities, Issues, and Challenges. Critical Reviews in Therapeutic Drug Carrier Systems, 32(5), 363–387 (2015).
Patwardhan B, Mashelkar RA. Traditional medicine-inspired approaches to drug discovery: Can Ayurveda show the way forward. Drug Discovery Today 2009;14(15/16):804-11.)
Johri RK, Zutshi U. An Ayurvedic formulation ‘Trikatu’ and its constituents. J Ethnopharmacol 1992;37:85-91.
Khanuja SPS, et al. Nitrile glycoside useful as a bioenhancer of drugs and nutrients, process of its isolation from moringa oleifera. US Patent 6858588. Council of Scientific and Industrial Research, New Delhi, IN. Feb 22, 2005.)
Randhawa, Gurpreet Kaur, and Jagdev Singh Kullar. "Bioenhancers from mother nature and their applicability in modern medicine." International journal of applied and basic medical research 1.1 (2011): 5-10.
Kapil, Randhir S., et al. "Process for preparation of pharmaceutical composition with enhanced activity for treatment of tuberculosis and leprosy." U.S. Patent No. 5,439,891. 8 Aug. 1995.
Atal N, Bedi KL. Bioenhancers: Revolutionary concept to market. J-AIM 2010;1(2)96-9.)
Qazi GN, Bedi KL, Johri RK, Tikoo MK, Tikoo AK, Sharma SC et al. Council of Scientific and Industrial Research. Bioavailability/ Bioefficacy Enhancing Activity of Cuminium cyminum and Extracts and Fractions Thereof. US Patent 52873;2004:Mar18.)
Atal N, Bedi KL. Bioenhancers: Revolutionary concept to market. J-AIM 2010;1(2)96-99.
Singha Ratndeep et al. Indian Herbal Bioenhancers: A Review: Pharmacognocy. 2009:80-82.
Vinson JA et al. Effect of Aloe Vera preparations on the human bioavailability of vitamin C and vitamin E. Phytomedicine2005;12(10):760-765.
Qazi G.N., et al. Bioavailability enhancing activity of Zingiber officinale and its extracts/fractions thereof. Date of Publication: 11/09/2003. US Patent No , US2003/0170326A1.
Qazi G.N., et al. Bioavailability enhancing activity of Carum carvi extracts and fractions thereof. Date of Publication: 11/12/2003. US Patent No , US20030228381A1.
Qazi G.N., et al. Bioavailability/bioefficacy enhancing activity of Cuminum cyminum and extracts and fractions thereof. Date of Publication: 07/04/2009. US Patent No , US007514105B2.
J. S. Choi and X. Li. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. International Journal of Pharmaceutics 2005;297(1-2):1-8.
X. Li and J. S. Choi, “Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats,” International Journal of Pharmaceutics, 2007;337(1-2):188–193.
S. C. Lim and J. S. Choi, “Effects of naringin on the pharmacokinetics of intravenous paclitaxel in rats,” Biopharmaceutics and Drug Disposition, vol. 27, no. 9, pp. 443–447, 2006.
Z. Q. Liu, H. Zhou, L. Liu et al., “Influence of co-administrated sinomenine on pharmacokinetic fate of paeoniflorin in unrestrained conscious rats,” Journal of Ethnopharmacology, 2005;99(1):61–67
Qiu W, et al. Effect of berberine on pharmacokinetics of digoxin after oral administration to rats. Chinese Journal of Chinese Materia Medica. 2011;36(7):918-21.
Imai T, Sakai M, Ohtake H, Azuma H, Otagiri M. In vitro and in vivo evaluation of the enhancing activity of glycyrrhizin on the intestinal absorption of drugs. Pharm Res. 1999 Jan;16(1):80-6.
Grabovac V, Schmitz T, Föger F, Bernkop-Schnürch A. Papain: an effective permeation enhancer for orally administered low molecular weight heparin. Pharm Res. 2007 May;24(5):1001-6.
Khanuja S.P.S., et al. Nitrile glycoside useful as a bioenhancer of drugs and nutrients, process of its isolation from Moringa oleifera. Date of Publication: 22/02/2005. United States Patent Number, US006858588B2.
Khanuja S.P.S., et al. Antibiotic pharmaceutical composition with lysergol as bioenhancer and method of treatment. Date of Publication: 15/03/2007. United States Patent Number, 20070060604A1.
Gokaraju, G.R., Gokaraju, R.R., D‟souza, C., Frank, E., 2010. Bioavailability/bioefficacy enhancing activity of Stevia rebaudiana and extracts and fractions and compounds thereof. Date of Publication: 06/05/2010. US Patent No , US20100112101A1.
Ogita A, Fujita K, Taniguchi M, Tanaka T. combined action of Allicin and Amphotericin B exhibited enhanced antifungal activity against S. cerevisiae. Planta Med 2006;72:1247-50.
Van Gelder J, et al. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos. 2000;28(12):1394-6.
W. Reanmongkol, W. Janthasoot, W. Wattanatorn, P. Dhumma-Upakorn, and P. Chudapongse, “Effects of piperine on bioenergetic functions of isolated rat liver mitochondria,” Biochemical Pharmacology, vol. 37, no. 4, pp. 753–757, 1988.
D. S. Jamwal and J. Singh, “Effects of piperine on enzyme activities and bioenergetic functions in isolated rat livermitochondria and hepatocytes,” Journal of Biochemical Toxicology, vol. 8, no. 4, pp. 167–174, 1993.
A. R. Annamalai and R.Manavalan, “Effects of “Trikatu” and its individual components and piperine on gastro intestinal tracts: trikatu: a bioavailable enhancer,” Indian Drugs, vol. 27, no. 12, pp. 595–604, 1990.
R. K. Johri, N. Thusu, A. Khajuria, and U. Zutshi, “Piperine mediated changes in the permeability of rat intestinal epithelial cells. The status of γ-glutamyl transpeptidase activity, uptake of amino acids and lipid peroxidation,” Biochemical Pharmacology, vol. 43, no. 7, pp. 1401–1407, 1992.
M. Majeed, V. Badmaev, and R. Rajendran, “Use of piperine to increase bioavailability of nutritional compounds,” United States Patent Number, US005536506A, 1996.
S. Bajad, K. L. Bedi, A. K. Singla, and R. K. Johri, “Piperine inhibits gastric emptying and gastrointestinal transit in rats and mice,” Planta Medica, vol. 67, no. 2, pp. 176–179, 2001.
C. K. Atal, R. K. Dubey, and J. Singh, “Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism,” Journal of Pharmacology and Experimental Therapeutics, vol. 232, no. 1,pp. 258–262, 1985.
R. K. Reen, D. S. Jamwal, S. C. Taneja et al., “Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine,” Biochemical Pharmacology, vol. 46, no. 2, pp. 229–238, 1993.
R. K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S. K. Gupta, and M. F. Fromm, “Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 2, pp. 645–650, 2002.
A. Khajuria, N. Thusu, and U. Zutshi, “Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics,” Phytomedicine, vol. 9, no. 3, pp. 224–231, 2002.
Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. 2013. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447:75-93.
Hochman J, Artursson P. Mechanisms of absorption enhancement and tight junction regulation. J Control Release. 1994;29(3):253–67.
Kathryn Whitehead, Natalie Karr, Samir Mitragotri. Discovery of synergistic permeation enhancers for oral drug delivery. Journal of Controlled Release 128 (2008) 128-133.
Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev. 2006 Apr 20;58(1):15–28.
Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: structure activity and structure-toxicity relationships for phenoxypolyoxyethylene surfactant permeability enhancers. Pharm Res. 1994 Oct;11(10):1501–4.
Bohets H, Annaert P, Mannens G, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K. Strategies for absorption screening in drug discovery and development. Curr Top Med Chem. 2001;1(5):367–83.
Uchiyama T, et al. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoside. J Pharm Pharmacol. 1999 Nov;51(11):1241–50.
Bowe CL, et al. Design of compounds that increase the absorption of polar molecules. Proc Natl Acad Sci USA. 1997;94(22):12218–23.
Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm Res. 1994 Aug;11(8):1132-42.
Anderberg EK, Nyström C, Artursson P. 1992. Epithelial transport of drugs in cell culture. VII: Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial(Caco-2) cells. J Pharm Sci 81:879-887.
Hamid KA, Katsumi H, Sakane T, Yamamoto A. 2009. The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats. Int J Pharm 379:100-108.
Sakai M, Imai T, Ohtake H, Azuma H, Otagiri M. 1998. Effects of absorption enhancers on cytoskeletal actin filaments in Caco-2 cell monolayers. Life Sci 63:45-54.
Kotze´, A.F., Luessen, H.L., De Boer, A.G., Verhoef, J.C., Junginger, H.E., 1998a. Chitosan for enhanced intestinal permeability: Prospects for derivatives soluble in neutral and basic environments. Eur. J. Pharm. Sci. 7, 145–151.
Kotze´, A.F., Luessen, H.L., De Leeuw, B.J., De Boer, A.G., Verhoef, J.C., Junginger, H.E., 1998b. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal cells (Caco-2). J.Contr. Rel. 51, 35–46.
Thanou, M., Verhoef, J.C., Romeijn, S.G., Nagelkerke, J.F., Merkus, F.W.H.M., Junginger, H.E., 1999. Effects of Ntrimethyl chitosan chloride, a novel absorption enhancer, on Caco-2 intestinal epithelia and the ciliary beat frequency of chicken embryo trachea. Int. J. Pharm. 185, 73–82.
C. Jonker, J.H. Hamman, A.F. Kotze. Intestinal paracellular permeation enhancement with quaternised chitosan: in situ and in vitro evaluation. International Journal of Pharmaceutics 238 (2002) 205–213.)
Ana Polache. Intestinal Absorption Enhancement Via the Paracellular Route by Fatty Acids, Chitosans and Others: A Target for Drug Delivery. Current Drug Delivery, 2005, 2, 9-22.)
María José Cano-Cebrián, Teodoro Zornoza, Luis Granero and Ana Polache. Intestinal Absorption Enhancement Via the Paracellular Route by Fatty Acids, Chitosans and Others: A Target for Drug Delivery. Current Drug Delivery, 2005, 2, 9-22.)
Anilkumar P, et al. A rationalized description on study of intestinal barrier, drug permeability and permeation enhancers. Journal of Global Trends in Pharmaceutical Sciences,2011,2(4)431-49.
Misra A at al. Oral Absorption Promoters: Opportunities, Issues, and Challenges. Critical Reviews in Therapeutic Drug Carrier Systems, 32(5), 363–387 (2015).
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Amir, . F., Suhron, M., & Sulaihah, S. (2021). Family care model development in treating schizophrenia patients that have self-deficit nursing based system: Structural equation modeling analysis. International Journal of Health & Medical Sciences, 5(1), 7-14. https://doi.org/10.21744/ijhms.v5n1.1808
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
